1UN
Categorie
1UN Les marques, 1UN Analogs
1UN Les marques melange
1UN Formule chimique
C32H45N3O4S
1UN RX lien
http://www.rxlist.com/cgi/generic2/nelfin.htm
1UN FDA fiche
1UN msds (fiche de securite des materiaux)
1UN Synthese de reference
Aucune information disponible
1UN Poids moleculaire
567.784 g/mol
1UN Point de fusion
349.84 oC
1UN H2O Solubilite
Légèrement soluble
1UN Etat
Solid
1UN LogP
5.247
1UN Formes pharmaceutiques
Tablet (orale - 250 mg, 625 mg); Poudre (oral)
1UN Indication
Utilisé en combinaison avec d'autres médicaments antiviraux dans le traitement du VIH chez les adultes et les enfants.
1UN Pharmacologie
Le nelfinavir est un inhibiteur de protéase ayant une activité contre virus d'immunodéficience humaine de type 1 (VIH-1). Les inhibiteurs de protéase bloquent la partie appelée protéase du VIH. VIH-1 de la protéase est une enzyme requise pour la le clivage protéolytique des précurseurs dans la polyprotéine virale fonctionnelle des protéines individuelles dans infectieuses VIH-1. Le nelfinavir se lie au site de la protéase active et inhibe l'activité de l'enzyme. Cette inhibition empêche le clivage des polyprotéines viraux résultant en la formation d'immatures non-particules virales infectieuses. Les inhibiteurs de protéase sont presque toujours utilisés en combinaison avec au moins deux autres médicaments anti-VIH.
1UN Absorption
Eh bien absorbé après administration orale.
1UN Toxicite
DL50 par voie orale est plus 5g/kg chez le rat. Les effets secondaires incluent la soif et la faim, la perte de poids inexpliquée, augmentation de la miction, la fatigue et peau sèche et irritée.
1UN Information pour les patients
PATIENT INFORMATION
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
1UN Organismes affectes
Virus d'immunodéficience humaine
